Syntara reports encouraging early Parkinson's trial results
Syntara has reported statistically significant reductions in brain inflammation in an early-stage Parkinson's disease study.
Market Cap $1.028B
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
